Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab plus verteporfin photodynamic therapy for retinal angiomatous proliferation due to age-related macular degeneration
2006-004367-57Phase 4Completed
- Sponsor
- Department of Ophthalmology, Medical University of Graz
- Start
- Apr 2008
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab and verteporfin in exudative macular degeneration and retinal angiomatous proliferation (RAP), sponsored by Department of Ophthalmology, Medical University of Graz. Primary endpoints: Change in visual acuity from baseline at 12 months and Mean change from baseline in best corrected visual acuity at 6 months. Started Apr 2008; status: completed.
02
Drugs
ranibizumabverteporfin
03
Conditions
exudative macular degenerationretinal angiomatous proliferation (RAP)
Beyond the preview
Go deeper on 2006-004367-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004367-57.